

### Market Snapshot (Updated at 8AM)\*

Indian Indices	Close	Net Chng.	Chng. (%)
Sensex	39728.41	1066.33	2.61
Nifty	11680.35	290.70	2.43

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	28494.20	19.80	0.07
NASDAQ COM.	11713.87	54.86	0.47
FTSE 100	5832.52	102.54	1.73
CAC 40	4837.42	104.24	2.11
DAX	12703.75	324.31	2.49
NIKKEI 225	23519.11	11.00	0.05
SHANGHAI	3337.31	5.51	0.17
HANG SENG	24262.86	102.88	0.43

Currency	Close	Net Chng.	Chng. (%)
USD / INR	73.38	0.08	0.10
USD / EUR	1.17	0.00	0.09
USD / GBP	1.29	0.00	0.20
USD / JPY	105.28	0.11	0.10

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1906.83	1.83	0.10
Silver	24.43	0.21	0.87

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	40.73	0.20	0.49
Brent Crude	42.87	0.25	0.58
Natural Gas	2.78	0.00	0.14

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	5.90	0.01	0.09

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	68.32	1.49	2.13
HDFC Bank	55.40	1.01	1.79
ICICI Bank	10.87	0.26	2.34
Infosys Ltd	15.26	1.10	6.72
Tata Motors	8.81	0.11	1.23
Vedanta Ltd	5.11	0.12	2.29
Wipro	5.03	0.08	1.57

### Institutional Flow (In Crore) 15-10-2020

Institution	Purchase	Sale	Net
FII	6544.15	7148.22	604.07
DII	3251.11	4059.40	808.29

### Key Contents

- ⇒ [Market Outlook/Recommendation](#)
- ⇒ [Today's Highlights](#)
- ⇒ [Global News, Views and Updates](#)
- ⇒ [Links to important News highlight](#)

### Top News for Today

- **AstraZeneca Pharma:** To launch Calquence in India on October 21. Company had received import and market permission from Drugs Controller General of India on March 12. The drug is used to treat various types of blood cancer.
- **UPL:** KPMG has resigned as the auditor with effect from October 8 for company's material arm in Mauritius - UPL Corporation.
- **Sun Pharma:** Clarified on the news of SEBI probe of its ex-board member Ashwin Dani, saying that it has not received any information or notice either from SEBI or anyone regarding the matter.
- **Bharti Airtel:** Competition Commission of India approves completion of first closing of the company's arm Nextra Data to the Carlyle group. The company on July 1 had announced that the Carlyle Group will acquire 25% stake in the company's data centre business at a valuation of \$1.2 billion.
- **Persistent Systems:** To acquire entire business of U.S.-based Capiot Software for \$6.34 million. Additional incentive-based payments for the next three years amount to another 6 million. The acquisition is subject to customary closing conditions and is likely to be completed within 2-4 weeks.
- **Mindtree:** Has appointed Dayapatra Nevatia, Chief Operating Officer as Executive Director (Additional Director) of the company till October 2025.

### Events of the Day

- **Result for today:** Bajaj Consumer Care, Federal Bank, Phillips Carbon Black, IIFL Securities, Shoppers Stop, Tata Communications, Tintplate, Uniply Industries, Shakti Pumps, HCL Technologies
- **Conference call:** 10:30 AM South Indian Bank, 4:30 PM Federal Bank, 5:00 PM HCL Tech
- **Asian Granito:** To meet Aditya Birla Money on October 16.

## Market in Detailed (Updated at 8AM)\*

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	39728.41	1066.33	2.61	1.13	1.08	8.93	2.93
Nifty	11680.35	290.70	2.43	1.30	0.65	8.76	1.89
BSE M Cap	14468.88	257.38	1.75	2.42	3.83	8.59	3.94
BSE S Cap	14643.95	215.58	1.45	2.44	5.10	15.83	14.41
Nifty MC 100	16599.60	286.65	1.70	3.19	4.89	10.42	6.37
BSE Auto	17936.90	229.65	1.26	3.01	2.68	12.97	4.26
BSE Capgoods	13505.44	291.06	2.11	0.91	4.60	5.51	25.36
BSE FMCG	10965.92	121.04	1.09	1.74	4.02	4.87	6.22
BSE Metal	7912.62	62.89	0.79	3.70	10.01	5.23	11.03
BSE Oil&Gas	11755.19	135.36	1.14	2.75	11.23	7.08	22.02
BSE Healthcare	19653.37	343.45	1.72	4.17	0.15	16.00	58.51
BSE Power	1592.09	15.17	0.94	2.34	7.12	6.01	17.01
BSE Realty	1652.92	39.45	2.33	4.31	7.71	7.27	16.20
BSE ConsDur	24033.62	153.99	0.64	2.15	1.08	17.20	7.81
BSE Bank	26169.76	894.65	3.31	0.39	2.12	6.97	18.89
BSE IT	21716.56	596.08	2.67	0.68	9.43	26.30	41.67

LME	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1906.83	1.83	0.10	1.22	2.67	6.11	27.97
Silver(\$/Ounce)	24.26	0.03	0.14	3.52	10.64	26.69	39.47
Aluminium	1839.60	4.60	0.25	2.81	5.10	11.58	7.11
Copper	6738.15	35.65	0.53	0.90	0.58	5.63	17.39
Zinc	2409.75	9.00	0.37	2.67	2.63	9.95	1.97
Lead	1756.10	22.40	1.26	1.16	6.65	3.95	18.11

Currency	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.38	0.08	0.10	0.19	0.36	2.41	2.50
USD Index	93.79	0.07	0.07	0.79	0.62	2.65	4.30
YUAN	6.72	0.00	0.03	0.42	0.47	3.97	5.51
GBP	1.29	0.00	0.10	1.07	0.55	2.73	0.50
EUR	1.17	0.00	0.00	1.00	0.91	2.85	5.74
YEN	105.28	0.17	0.16	0.32	0.31	1.89	3.31

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	109.50	0.10	0.09	0.68	10.10	9.72	2.15
Cotton	69.32	0.10	0.14	2.48	4.44	10.84	4.10
Sugar	14.18	0.02	0.14	0.07	11.57	13.44	4.42
Wheat	619.50	1.25	0.20	4.34	14.30	14.56	14.04
Soybean	1060.50	1.25	0.12	0.47	4.48	18.52	9.05

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	28494.20	19.80	0.07	0.24	1.65	6.58	5.53
Nasdaq	11713.87	54.86	0.47	2.56	6.00	11.84	44.19
S&P 500	3483.34	5.33	0.15	1.06	2.89	8.33	16.51
FTSE100	5832.52	102.54	1.73	2.43	4.05	6.69	18.63
CAC40	4837.42	104.24	2.11	1.52	4.67	4.87	15.09
DAX	12703.75	324.31	2.49	2.60	4.16	1.33	0.27
Mexico IPC	38059.23	33.51	0.09	0.90	3.62	4.37	12.58
Brazil Bovespa	99054.10	280.37	0.28	3.69	0.62	1.49	6.04
Russian RTS	1132.29	28.01	2.41	2.29	9.55	7.18	15.97
Japan Nikkei	23519.11	11.00	0.05	0.43	0.18	3.28	4.65
Hang Seng	24262.86	102.88	0.43	0.28	1.88	2.84	9.01
Taiwan Index	12846.44	18.68	0.15	0.32	1.00	5.67	15.08
Shanghai Comp	3337.31	5.51	0.17	2.01	1.64	3.97	12.05
KOSPI	2347.78	12.48	0.53	1.81	3.58	7.55	12.77
Malaysia KLCI	1517.35	3.34	0.22	0.85	0.91	3.05	3.66
Jakarta Comp	5112.35	5.84	0.11	1.13	1.04	0.25	17.16
Philippine SE	5923.93	14.40	0.24	0.13	0.38	3.64	25.16
Thai Exch	1242.96	21.03	1.66	1.64	3.91	7.78	23.95

Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1637.00	95.00	5.48	16.90	27.79	3.65	13.71
Baltic Dirty	414.00	2.00	0.49	0.72	7.59	18.66	74.77
SG Dubai HY	0.58	0.57	5700.00	6.45	0.00	323.08	41.46

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	40.73	0.20	0.49	0.39	1.49	0.02	23.61
BRENT Crude	42.87	0.25	0.58	0.14	0.28	2.17	24.25
Natural Gas	2.78	0.00	0.14	1.39	4.32	18.26	15.36

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.73	0.00	0.00	5.36	5.07	18.71	57.91
UK	0.18	0.04	18.18	37.72	17.05	8.43	74.06
Brazil	3.56	0.02	0.45	0.20	4.80	25.48	8.53
Japan	0.03	0.01	34.78	13.89	47.62	19.23	119.26
Australia	0.74	0.02	3.00	12.59	14.40	15.76	29.17
India	5.90	0.01	0.09	0.66	2.19	1.46	9.18
Switzerland	0.55	0.03	6.03	10.55	16.21	26.16	11.96
Germany	0.61	0.03	4.99	16.64	27.35	37.39	46.28

**Taking global cues, Nifty is expected to open positive around 11,750 and likely to remain weak below 11,800. Downside supports are placed around 11,650 and 11,550.**

The Nifty previous session ended 2.43% down at 11,680.35. It opened on a flat note and continued declining towards finishing off below 11,800 levels. Ending the day with a huge bearish candle below 11,800 is pointing towards next round of retracement. Needless to say 11,800 may now continue to act as the major resistance. Downside supports are placed around 11,650 and 11,550 levels.

On the Nifty hourly chart; sharply down trending RSI while -DI +DI bearish crossover is done, which is pointing towards further decline. Hence staying cautious on rise is advised.

Nifty patterns on multiple time frames suggest; it ended with a huge bearish candle below 11,800 levels. Chart pattern suggests it might get into trading band of 11,800-11,650 with negative bias.

The Bank Nifty previous session ended 3.36% down at 23,072.40. It might get into the trading range of 22,400-23,500.

### **Nifty Crucial Supports & Resistances-**

**Supports- 11650, 11550 Resistances- 11750, 11800**

### **Open positional calls-**

T+5 Positional Sell-

| Futures Segment | BEL Fut @ 96-97, TGT- 87, SL- above 102

- **AstraZeneca Pharma:** To launch Calquence in India on October 21. Company had received import and market permission from Drugs Controller General of India on March 12. The drug is used to treat various types of blood cancer.
- **UPL:** KPMG has resigned as the auditor with effect from October 8 for company's material arm in Mauritius - UPL Corporation.
- **Sun Pharma:** Clarified on the news of SEBI probe of its ex-board member Ashwin Dani, saying that it has not received any information or notice either from SEBI or anyone regarding the matter.
- **Bharti Airtel:** Competition Commission of India approves completion of first closing of the company's arm Nxtra Data to the Carlyle group. The company on July 1 had announced that the Carlyle Group will acquire 25% stake in the company's data centre business at a valuation of \$1.2 billion.
- **Persistent Systems:** To acquire entire business of U.S.-based Capiot Software for \$6.34 million. Additional incentive-based payments for the next three years amount to another 6 million. The acquisition is subject to customary closing conditions and is likely to be completed within 2-4 weeks.
- **Mindtree:** Has appointed Dayapatra Nevatia, Chief Operating Officer as Executive Director (Additional Director) of the company till October 2025.

### **Stocks Drift Amid Virus Jitters, Stimulus Deadlock**

Asian stocks and U.S. futures were mixed Friday as investors mulled continued talks over U.S. stimulus and the economic impact of fresh restrictions in some parts of the world to fight the resurgent coronavirus. Shares dipped in Tokyo, Sydney and Seoul, while Hong Kong saw modest gains. S&P 500 futures edged higher after the benchmark came off its session lows as banks rebounded from a two-day selloff and energy shares rallied. U.S. small-cap shares pushed higher while the Nasdaq underperformed. Treasuries and the dollar were steady, while crude oil ticked lower. President Donald Trump said he is willing to go beyond the \$1.8 trillion offer for relief that's already been put forward, but Senate Majority Leader Mitch McConnell rejected that. Treasury Secretary Steven Mnuchin told Pelosi Trump will personally lobby to get reluctant Senate Republicans behind any stimulus deal they reach.

### **Oil Stuck Near \$41 With Demand Woes Capping Stockpiles Rally**

Oil headed for a modest weekly advance on the back of shrinking American stockpiles, but gains were capped by the prospect of a resurgent virus forcing more stay-at-home measures in Europe and the U.S. Futures in New York traded near \$41 a barrel and are up less than 1% this week. The Energy Information Administration reported a bigger-than-expected 3.8 million barrel decline in crude inventories. Distillate stockpiles fell by the most since 2003, spurring optimism the supply situation is tightening. Covid-19 is surging in Europe, however, with tighter restrictions being imposed in London and Paris. In the U.S., cases are spiking again in the Midwest, while applications for state unemployment benefits unexpectedly jumped last week to the highest since August. Adding to the gloomy price outlook, Libyan oil production is said to have reached about 500,000 barrels a day.

### **Libya's Oil Output Reaches 500,000 Barrels a Day After Truce**

Libya's daily oil production has risen to around 500,000 barrels, according to people familiar with the situation, as the war-battered nation restarts its energy industry after a truce. Sharara, the country's biggest oil field, is pumping roughly 110,000 barrels a day, according to two people with knowledge of the situation, who asked not to be identified because they're not authorized to speak to media. The southwestern deposit, which has a capacity of 300,000 barrels daily. Brent crude fell following the news but later pared some losses. The international benchmark was 0.6% lower late Thursday at \$43.06 a barrel. The halt in Libya's civil war led to many fields and ports in the east reopening last month, after an almost total shutdown of energy facilities since January. Before then, Libya was producing 1.2 million barrels a day. Libya is home to Africa's largest crude reserves and the return of its barrels is weighing on oil prices just as tighter virus restrictions in many countries sap demand for energy. The North African nation is an OPEC+ member, though it's exempt from supply curbs the cartel initiated in May to boost oil prices, which are down around 35% this year.

### **Remdesivir Found Ineffective; Europe Sets Curbs**

Remdesivir has no definite effect on a hospitalized patient's chances of survival, a clinical trial by the World Health Organization found. The outbreak's march across the U.S. Midwest has caught up with the region's most populous states. Illinois, Ohio and Michigan have proven unable to fend off outbreaks at their doorsteps. The U.K. government imposed tougher curbs on London while France set a curfew in Paris as more European nations reported some of the highest number of new cases since the outbreak's peak in spring. Democratic vice presidential nominee Kamala Harris canceled her travel until Monday after her communications director and a flight crew member tested positive. A passenger on Joe Biden's campaign plane tested positive, though the two didn't come near each other -- and he tested negative Thursday.

### Rubber Set for Weekly Advance on Tight Supply and China Buying

Rubber futures in Singapore headed for a second week of gains as the coronavirus pandemic tightens supply in key producers and demand from top importer China accelerates. “Rubber prices are supported by the lack of raw latex since August, which is mainly caused by the impact of Covid-19, as well as a recovery in Chinese demand since September,” said Gu Jiong, an analyst at Yutaka Shoji, a broker in Tokyo. “Demand for rubber gloves is growing but latex supply for sheet and block rubber has dropped by over 10%. This may underpin the market in the short term,” he said. Consumption of rubber is expected to improve in the last four months of the year due to a restoration of economic activity and a faster-than-expected economic recovery in China, where the automobile sector has “made a major turnaround,” according to the Association of Natural Rubber Producing Countries Wednesday.

### Auto / Auto Ancillaries

[Toyota rolls out special offers for salaried customers ahead of festive season](#)

[Luxury carmaker BMW's steady path to recovery post COVID-induced lockdown](#)

[Mahindra launches Treo electric auto in Karnataka](#)

### Banking & Finance

[CFO, three others allege fraud at Sambandh Finserve](#)

[Govt seeks approval from Cabinet Committee on Economic Affairs on lowering stake in IDBI Bank](#)

[Banks need Artificial Intelligence for corporate lending: Krishnamurthy Subramanian, Chief Economic Advisor](#)

[Indian Bank follows SBI, sets up portal to restructure retail loans](#)

[Indian Bank inks MoU with Ministry, SIDBI for street vendors](#)

### Oil & Gas

[Bharat Petroleum tries to cut dependence on LPG from the Middle East](#)

[Numaligarh Refinery inked pipeline right to use agreement with GAIL](#)

[Saudi Aramco, Adnoc committed to \\$44 billion west coast refinery project: IOC Chairman](#)

[Fitch expects marketing, refining volume of oil firms to fall 15% in FY21](#)

### Metals/Mining/Power

[RK Singh: Executing a powerful reforms agenda](#)

[Adani Green-Total JV takes over Essel's solar assets acquired by Adani earlier](#)

[Jindal Stainless launches campaign to curb counterfeit products, market share to go up to 60% in FY22](#)

### IT/Telecom/Media

[Inox, Cinepolis open few properties, PVR and Carnival to start from 16th](#)

[Next one-month challenging but cinemas will bounce back: PVR Ltd JMD Sanjeev Bijli](#)

[SC seeks answers from govt on PIL seeking board to regulate Amazon Prime, Netflix content](#)

[Telcos say Trai must look at floor price demand](#)

[Vodafone Idea services in Maharashtra partially disrupted as key site in Pune gets flooded](#)

### FMCG/Retail/Textile/Food

[Apparel exporters' turnover to dip 25 pc in FY21, domestic retailers to see 40 pc revenue fall: Icra](#)

[From laptops to grinders, it's up & up again since May: Reliance Digital](#)

[Reliance's retail arm receives Rs 5,550 crore from KKR for 1.28% stake sale](#)

### Pharma/Fertilizers/Healthcare/Chemical

[Drug regulator asks Serum Institute to submit more information on Oxford Covid-19 vaccine](#)

[Natco Pharma eyes launch of 8-10 new drugs in India yearly](#)

[WHO study says remdesivir did not cut hospital stay or mortality in COVID-19 patients](#)



### Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

**Sudipto Datta, Compliance Officer**

**SMIFS Limited.**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com) | Website: [www.smifs.com](http://www.smifs.com)